Cargando…

Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors: Fc-mediated avidity enhances the potency of an anti-TLR4 antibody

In order to treat Toll like receptor 4 (TLR4)-mediated diseases, we generated a potent antagonistic antibody directed against human TLR4, Hu 15C1. This antibody's potency can be modulated by engaging not only TLR4 but also Fcγ receptors (FcγR), a mechanism that is driven by avidity and not cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loyau, Jérémy, Malinge, Pauline, Daubeuf, Bruno, Shang, Limin, Elson, Greg, Kosco-Vilbois, Marie, Fischer, Nicolas, Rousseau, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2014
Materias:	Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622919/ https://www.ncbi.nlm.nih.gov/pubmed/25484053 http://dx.doi.org/10.4161/19420862.2014.975098

Ejemplares similares

Therapeutic Effects of Treatment with Anti-TLR2 and Anti-TLR4 Monoclonal Antibodies in Polymicrobial Sepsis
por: Lima, Cristiano Xavier, et al.
Publicado: (2015)

Rational engineering of Fc/Fc receptor interactions to improve antibody potency
por: Doberstein, S, et al.
Publicado: (2003)

Role of Homologous Fc Fragment in the Potency and Efficacy of Anti-Botulinum Antibody Preparations
por: Torgeman, Amram, et al.
Publicado: (2017)

Boosting therapeutic potency of antibodies by taming Fc domain functions
por: Kang, Tae Hyun, et al.
Publicado: (2019)

Enhancing the Anti-tumor Potency of a Novel Siglec-15 Antibody by Engineering its Fc-mediated Effector Functions
por: Ding, Huandi, et al.
Publicado: (2023)

Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
por: Radić, Laura, et al.
Publicado: (2023)

Fc-binding antibody-recruiting molecules exploit endogenous antibodies for anti-tumor immune responses
por: Sasaki, Koichi, et al.
Publicado: (2020)

Increased half-life and enhanced potency of Fc-modified human PCSK9 monoclonal antibodies in primates
por: Shen, Yijun, et al.
Publicado: (2017)

Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain
por: Camelliti, Simone, et al.
Publicado: (2021)

Engineering pan–HIV-1 neutralization potency through multispecific antibody avidity
por: Rujas, Edurne, et al.
Publicado: (2022)

Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy
por: Sato, Yosuke, et al.
Publicado: (2022)

Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering
por: Heckel, Franziska, et al.
Publicado: (2022)

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
por: Arce Vargas, Frederick, et al.
Publicado: (2018)

A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated disease
por: Hatterer, Eric, et al.
Publicado: (2016)

Specific peptide conjugation to a therapeutic antibody leads to enhanced therapeutic potency and thermal stability by reduced Fc dynamics
por: Kiyoshi, Masato, et al.
Publicado: (2023)

Therapeutic Efficacy of Antibodies Lacking FcγR against Lethal Dengue Virus Infection Is Due to Neutralizing Potency and Blocking of Enhancing Antibodies
por: Williams, Katherine L., et al.
Publicado: (2013)

The Antitumor Activities of Anti-CD47 Antibodies Require Fc-FcγR interactions
por: Osorio, Juan C., et al.
Publicado: (2023)

IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody
por: Richardson, Simone I., et al.
Publicado: (2019)

HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function
por: Richardson, Simone I., et al.
Publicado: (2021)

Correction: Therapeutic Efficacy of Antibodies Lacking Fc. Receptor Binding against Lethal Dengue Virus Infection Is Due to Neutralizing Potency and Blocking of Enhancing Antibodies
por: Williams, Katherine L., et al.
Publicado: (2013)

Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions
por: Schriek, Angela I., et al.
Publicado: (2022)

Autoimmune mice make anti-Fc gamma receptor antibodies
Publicado: (1990)

TLR4-induced IFN-γ production increases TLR2 sensitivity and drives Gram-negative sepsis in mice
por: Spiller, Stephan, et al.
Publicado: (2008)

TLR4-induced IFN-γ production increases TLR2 sensitivity and drives Gram-negative sepsis in mice
por: Spiller, Stephan, et al.
Publicado: (2008)

The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein
por: Suzuki, Takuo, et al.
Publicado: (2021)

Treatment with anti‐neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice
por: Kasprick, Anika, et al.
Publicado: (2020)

Cross-Talk between TLR4 and FcγReceptorIII (CD16) Pathways
por: Rittirsch, Daniel, et al.
Publicado: (2009)

Corrigendum: Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions
por: Schriek, Angela I., et al.
Publicado: (2022)

FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies
por: Lang, Isabell, et al.
Publicado: (2022)

Development of an in Vitro Potency Assay for Anti-anthrax Lethal Toxin Neutralizing Antibodies
por: Whiting, Gail, et al.
Publicado: (2012)

Promoting Fc-Fc interactions between anti-capsular antibodies provides strong immune protection against Streptococcus pneumoniae
por: Aguinagalde Salazar, Leire, et al.
Publicado: (2023)

Pathogenic Exploitation of Fc Activity
por: Halstead, Scott B.
Publicado: (2014)

Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms
por: Pellerin, Alex, et al.
Publicado: (2015)

Cross-Linking GPVI-Fc by Anti-Fc Antibodies Potentiates Its Inhibition of Atherosclerotic Plaque- and Collagen-Induced Platelet Activation
por: Jamasbi, Janina, et al.
Publicado: (2016)

Humanized anti-TLR4 monoclonal antibody ameliorates lipopolysaccharide-related acute kidney injury by inhibiting TLR4/NF-κB signaling
por: Zhang, Qiuhua, et al.
Publicado: (2021)

Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies
por: Parsons, Matthew S., et al.
Publicado: (2018)

NMDA-receptor-Fc-fusion constructs neutralize anti-NMDA receptor antibodies
por: Steinke, Stephan, et al.
Publicado: (2023)

The influence of proline isomerization on potency and stability of anti-HIV antibody 10E8
por: Guttman, Miklos, et al.
Publicado: (2020)

Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions
por: Rowley, Tania F., et al.
Publicado: (2018)

The Fab Fragment of a Humanized Anti-Toll Like Receptor 4 (TLR4) Monoclonal Antibody Reduces the Lipopolysaccharide Response via TLR4 in Mouse Macrophages
por: Cai, Binggang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_farouu579midlhpuaou1ql1tpr